MAHALO results suggest positive treatment effect of lampalizumab in geographic atrophy

NEW ORLEANS – The 18-month results of the MAHALO study demonstrate a positive treatment effect of a complement inhibitor in AMD-related geographic atrophy, according to a speaker here. “The MAHALO results suggest the CFI biomarker is both prognostic for geographic atrophy progression and predictive for lampalizumab treatment response,” Carl D. Regillo, MD, FACS, said at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting.

Full Story →